Literature DB >> 27813521

Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option.

M Ashraf1, A Souka1, R Adelman2, S H Forster2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27813521      PMCID： PMC5306454          DOI： 10.1038/eye.2016.233

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  14 in total

1.  Efficacy of Ozurdex implant in recalcitrant diabetic macular edema--a single-center experience.

Authors:  Pooja Bansal; Vishali Gupta; Amod Gupta; Mangat Ram Dogra; Jagat Ram
Journal:  Int Ophthalmol       Date:  2015-08-02       Impact factor: 2.031

2.  Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.

Authors:  Chirag P Shah; Jeffrey S Heier
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2016-09-01       Impact factor: 1.300

3.  Dexamethasone intravitreal implants for diabetic macular edema refractory to ranibizumab monotherapy or combination therapy.

Authors:  L Gutiérrez-Benítez; E Millan; L Arias; P Garcia; E Cobos; M Caminal
Journal:  Arch Soc Esp Oftalmol       Date:  2015-05-23

4.  INTRAVITREAL DEXAMETHASONE IMPLANT FOR THE TREATMENT OF REFRACTORY MACULAR EDEMA IN RETINAL VASCULAR DISEASES: Results of the KKESH International Collaborative Retina Study Group.

Authors:  Saeed T Alshahrani; Rosa Dolz-Marco; Roberto Gallego-Pinazo; Manuel Diaz-Llopis; J Fernando Arevalo
Journal:  Retina       Date:  2016-01       Impact factor: 4.256

5.  Dexamethasone Intravitreal Implant for Chronic Diabetic Macular Edema Resistant to Intravitreal Bevacizumab Treatment.

Authors:  Yüksel Totan; Emre Güler; Fatma Betül Gürağaç
Journal:  Curr Eye Res       Date:  2015-01-22       Impact factor: 2.424

6.  Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema.

Authors:  José Cunha-Vaz; Paul Ashton; Raymond Iezzi; Peter Campochiaro; Pravin U Dugel; Frank G Holz; Michel Weber; Ronald P Danis; Baruch D Kuppermann; Clare Bailey; Kathleen Billman; Barry Kapik; Frances Kane; Ken Green
Journal:  Ophthalmology       Date:  2014-06-14       Impact factor: 12.079

7.  Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema.

Authors:  Ehsan Rahimy; Abtin Shahlaee; M Ali Khan; Gui-Shuang Ying; Joseph I Maguire; Allen C Ho; Carl D Regillo; Jason Hsu
Journal:  Am J Ophthalmol       Date:  2015-12-31       Impact factor: 5.258

8.  Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.

Authors:  John A Wells; Adam R Glassman; Allison R Ayala; Lee M Jampol; Neil M Bressler; Susan B Bressler; Alexander J Brucker; Frederick L Ferris; G Robert Hampton; Chirag Jhaveri; Michele Melia; Roy W Beck
Journal:  Ophthalmology       Date:  2016-02-27       Impact factor: 12.079

9.  Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.

Authors:  John A Wells; Adam R Glassman; Lee M Jampol; Lloyd Paul Aiello; Andrew N Antoszyk; Carl W Baker; Neil M Bressler; David J Browning; Crystal G Connor; Michael J Elman; Frederick L Ferris; Scott M Friedman; Michele Melia; Dante J Pieramici; Jennifer K Sun; Roy W Beck
Journal:  JAMA Ophthalmol       Date:  2016-02       Impact factor: 7.389

10.  Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant.

Authors:  Ratimir Lazic; Marko Lukic; Ivan Boras; Natasa Draca; Marko Vlasic; Nikica Gabric; Zoran Tomic
Journal:  Retina       Date:  2014-04       Impact factor: 4.256
View more
  2 in total

1.  Subthreshold micropulse laser versus intravitreal anti-VEGF for diabetic macular edema patients with relatively better visual acuity.

Authors:  Sezen Akkaya; Banu Açıkalın; Yusuf Emre Doğan; Fatih Çoban
Journal:  Int J Ophthalmol       Date:  2020-10-18       Impact factor: 1.645

2.  Functional and structural characteristics in patients with diabetic macular oedema after switching from ranibizumab to aflibercept treatment. Three year results in real world settings.

Authors:  Anastasios E Sepetis; Holly Clarke; Bhaskar Gupta
Journal:  Int J Retina Vitreous       Date:  2022-04-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.